McKesson Corporation (MCK)
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
McKesson (MCK) Stock Sinks As Market Gains: Here's Why
McKesson (MCK) closed the most recent trading day at $750.63, moving 3.74% from the previous trading session.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why McKesson (MCK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
McKesson Q4 Earnings Call Highlights
McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
